

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau


(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/211956 A1

(51) International Patent Classification:	63/058,345	29 July 2020 (29.07.2020)	US
	C07K 16/00 (2006.01)	29 July 2020 (29.07.2020)	US
	C12N 9/88 (2006.01)	28 January 2021 (28.01.2021)	US
(21) International Application Number:	63/142,987	28 January 2021 (28.01.2021)	US
	63/142,981	28 January 2021 (28.01.2021)	US
	63/142,983	28 January 2021 (28.01.2021)	US
(22) International Filing Date:	PCT/US2021/027666	28 January 2021 (28.01.2021)	US
	63/142,982	28 January 2021 (28.01.2021)	US
	63/142,985	28 January 2021 (28.01.2021)	US
(25) Filing Language:	English	(71) Applicant: JANSSEN BIOTECH, INC. [US/US];	
(26) Publication Language:	English	800/850 Ridgeview Drive, Horsham, PA 19044 (US).	
(30) Priority Data:	16 April 2021 (16.04.2021)	(72) Inventors: GANESAN, Rajkumar; 1400 Mckean Road,	
	63/011,991	Spring House, PA 19477 (US). ZWOLAK, Adam; 1400	
	63/011,993	Mckean Road, Spring House, PA 19477 (US). HO, Ja-	
	63/011,985	son; 1400 Mckean Road, Spring House, PA 19477 (US).	
	63/011,959	OBERMAJER, Natasa; Turnhoutseweg 30, 2340 Beerse	
	63/011,974	(BE). DIEM, Michael; 1400 Mckean Road, Spring House,	
	63/030,808	PA 19477 (US). SINGH, Sanjaya; 1400 Mckean Road,	
	63/030,765	Spring House, PA 19477 (US). VENKATARAMANI,	
	63/030,787	Sathyadevi; 597 Fawnview Circle, Blue Bell, PA 19422	
	63/030,823	(US). MCDEVITT, Theresa; 1400 Mckean Road, Spring	
	63/030,829	House, PA 19477 (US). SHEN, Fei; 1400 Mckean Road,	
	63/058,332	Spring House, PA 19477 (US).	
	63/058,354	(74) Agent: WEISSER, Tamera, M. et al.; Jones Day, 250	
	63/058,369	Vesey Street, New York, NY 10281-1047 (US).	

(54) Title: BIOSYNTHETIC GLYCOPROTEIN POPULATIONS



(57) Abstract: A population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue; and wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))